Top 5 Drug Type | Count |
---|---|
Autologous CAR-T | 5 |
γ-δT | 5 |
Universal CAR-T | 5 |
Nanobody | 4 |
CAR-T | 4 |
Target |
Mechanism FLT3 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD276 inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD7 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date18 May 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Anti-FLT3 CAR-T cell(PersonGen BioTherapeutics (Suzhou)) ( FLT3 ) | Relapsing acute myeloid leukemia More | Phase 1/2 |
UTAA09/17 ( CD19 ) | Scleroderma, Systemic More | Early Phase 1 |
UTAA-91 ( CD19 ) | Scleroderma, Systemic More | Early Phase 1 |
TAA16/13 | Anaplastic Large-Cell Lymphoma More | Preclinical |
UTAA06 ( CD276 ) | Solid tumor More | Preclinical |